0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > EGFRvIII

EGFRvIII

EGFRvIII Molecule Information

Name:Epidermal growth factor receptor variant III
Target Synonym:
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 2 Clinical

EGFRvIII Protein Product ListCompare or Buy

EGFRvIII Part of Bioactivity data

EGI-H52H4-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of anti-EGFRvIII CAR-293 cells were stained with 100 μL of 3 μg/mL of Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) and negative control protein respectively, washed and then followed by PE anti-His Tag antibody and analyzed with FACS (Routinely tested).

EGI-H52H4-ELISA
Human EGFRvIII, His TagHuman EGFRvIII, His Tag (Cat. No. EGI-H52H4) ELISA bioactivity

Immobilized Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) at 1 μg/mL (100 μL/well) can bind Anti-EGFRvIII Antibody , Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

EGI-H52H4-MALS-HPLC
Human EGFRvIII, His Tag (Cat. No. ) MALS images

The purity of Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) was more than 90% and the molecular weight of this protein is around 60-75 kDa verified by SEC-MALS.

Bioactivity-ELISA
Human EGFRvIII, His TagHuman EGFRvIII, His Tag (Cat. No. EGI-H52H4) ELISA bioactivity

Immobilized Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) at 1 μg/mL (100 μL/well) can bind Anti-EGFRvIII Antibody , Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

EGFRvIII Molecule Synonym Name

EGFRvIII

EGFRvIII Molecule Background

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.The type III EGF deletion-mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors; EGFR gene amplification is correlated with the structural rearrangement of the gene. The EGFRvIII gene has an in-frame deletion of 801 base pairs, corresponding to exons 2–7 in the mRNA, resulting in the deletion of amino acids 30-297 in the extracellular domain and the generation of a glycine at the fusion point

EGFRvIII References

EGFRvIII Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
EGFRvIII-CAR Phase 1 Clinical Duke University Medical Center Glioblastoma Details
Anti-EGFRvIII/CD3 BiTE antibody (Amgen) AMG-596 Phase 1 Clinical Amgen Inc Glioblastoma Details
Anti-EGFRvIII-CAR EGFRvIII CAR; Anti-EGFRvIII-CAR Phase 2 Clinical National Cancer Institute, Kite Pharma Glioblastoma Details
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) LXF-821 Phase 1 Clinical Novartis Pharma Ag, University Of Pennsylvania Glioblastoma Details
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) CPGJ-602; 602; CPGJ602; CPGJ 602 Phase 2 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Colorectal Neoplasms Details
GNC-039 GNC-039 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours; Glioma Details
EGFRvIII-CAR Phase 1 Clinical Duke University Medical Center Glioblastoma Details
Anti-EGFRvIII/CD3 BiTE antibody (Amgen) AMG-596 Phase 1 Clinical Amgen Inc Glioblastoma Details
Anti-EGFRvIII-CAR EGFRvIII CAR; Anti-EGFRvIII-CAR Phase 2 Clinical National Cancer Institute, Kite Pharma Glioblastoma Details
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) LXF-821 Phase 1 Clinical Novartis Pharma Ag, University Of Pennsylvania Glioblastoma Details
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) CPGJ-602; 602; CPGJ602; CPGJ 602 Phase 2 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Colorectal Neoplasms Details
GNC-039 GNC-039 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours; Glioma Details

This web search service is supported by Google Inc.

totop